Boston Scientific stock has fallen sharply over the past year, yet several valuation checks now suggest the shares may be pricing in a lot of bad news already. The market reaction to the recent cyberattack and softer demand for key products has been severe, while both intrinsic value estimates and market multiples currently lean more supportive.

• The stock is down 54.5% over the past year, which points to a heavy reset in expectations for Boston Scientific.
• The recent cyberattack and operational disruption may weigh on sentiment in the near term. Any progress on restoring systems and stabilising product demand can influence how quickly cash flow expectations recover.
• The broader checks lean cheap, with Boston Scientific screening as undervalued both on a Discounted Cash Flow (DCF) intrinsic value estimate and on market multiples, and a value score of 5 out of 6 reinforcing that picture.

The issue now is whether the current discount in Boston Scientific stock fairly reflects the cybersecurity and demand risks, or if the market has pushed the valuation too low relative to its intrinsic value estimates.

Compare Boston Scientific's reset valuation with other companies that also screen as potentially mispriced by reviewing the hand picked list of 51 high quality undervalued stocks.

Is Boston Scientific Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Boston Scientific is worth today based on projected future free cash flows. For the latest twelve months, Boston Scientific generated about $3.6b in free cash flow, and the model assumes these cash flows continue growing from this base rather than shrinking.

On these assumptions, the DCF points to an estimated intrinsic value of about $85 per share. Compared with the current share price, that implies roughly a 43.6% discount, which suggests the stock screens as undervalued on cash flow terms. The recent cyberattack and disruption to global operations help explain why the market is applying such a steep discount despite the cash flows that the DCF model projects.

On this DCF view, Boston Scientific stock currently looks undervalued relative to its projected cash flows.

Our Discounted Cash Flow (DCF) analysis suggests Boston Scientific is undervalued by 43.6%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Is Boston Scientific a Bargain on Earnings?

The P/E ratio is a useful cross check for Boston Scientific because earnings are a key focus for investors in established medical equipment businesses. Boston Scientific currently trades on a P/E of about 19.0x, which is below both the Medical Equipment industry average of 26.6x and the peer group average of 41.2x.

A fair P/E ratio for Boston Scientific, based on its sector, profitability profile and risk factors, is estimated at around 29.0x. That sits above the current 19.0x multiple and indicates that the stock trades at a discount to what this framework suggests could be reasonable. The gap implies the market is pricing Boston Scientific more cautiously than both its industry and the tailored fair multiple indicate.

On this earnings multiple view, Boston Scientific stock appears undervalued compared with both its industry and its modelled fair P/E level.

The Boston Scientific Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this Boston Scientific valuation puzzle leaves off and spell out what growth, margin and earnings paths would need to hold for the stock to be worth significantly more or less than it trades for today on the market, on Simply Wall St's Community page. Rather than relying on a single multiple or model output, each one lays out the assumptions behind its fair value so you can compare them with future results as they arrive.

The community is split on Boston Scientific, with some investors focused on acquisition upside while others flag product and execution risks.

Bull case: 51% undervalued

"The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons…"

Bear case: 9% overvalued

"However, management’s lower 2026 organic revenue guidance of 6.5% to 8% highlights that any benefit to top line growth could be uneven…"

Do you think there's more to the story for Boston Scientific? Head over to our Community to see what others are saying!

The Bottom Line

Boston Scientific screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and the current P/E multiple, which are pointing in the same direction. That agreement, together with the broader valuation checks, suggests the stock already reflects a meaningful amount of bad news. The key question from here is whether Boston Scientific can manage cybersecurity and demand risks well enough for investors to regain confidence in its cash flows and allow the valuation gap to close.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.